Aneel Ashrani is a Hematology physician affiliated with Mayo Clinic. OpenAlex indexes 194 publications with 5,545 citations (h-index 41).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
200 1st St SW
Rochester, MN 559050001
Telephone
507-284-2511Provider last certified this registry record 11 Aug 2020.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Kedrion Biopharma, Inc.Program year20251 payment
- Bio Products Laboratory USA, Inc.Program year20238 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
97.9%SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor97.9%Remdesivir100%Part B, office-administered≥17 patientsBlood & clotting
2.1%Factor Xa inhibitor1.6%Eliquis61%Xarelto39%Part D<11 patientsAntifibrinolytic Agent0.5%Tranexamic Acid100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2002–2019 per NIH RePORTER. The latest:
- Risk Factors for Venous Thromboembolism in the Community
Mayo Clinic Rochester
FY2019$694,657R01HL066216 - Risk Factors for Venous Thromboembolism in the Community
Mayo Clinic Rochester
FY2018$694,657R01HL066216 - Risk Factors for Venous Thromboembolism in the Community
Mayo Clinic Rochester
FY2017$694,655R01HL066216
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Cancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2024 - Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial
Journal of Thrombosis and Haemostasis
2024
Similar KOLs
Other experts from the same institution or the same specialty.
S Rajkumar, MD
Mayo Clinic
Bradley Boeve, MD
Mayo Clinic
Rick Nishimura, MD
Mayo Clinic
Victor Montori, MD
Mayo Clinic
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”